预约演示
更新于：2025-08-11
Olopatadine Hydrochloride
盐酸奥洛他定
更新于：2025-08-11
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (1996-12-18), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C21H24ClNO3 |
InChIKeyHVRLZEKDTUEKQH-NOILCQHBSA-N |
CAS号140462-76-6 |
关联
86
项与 盐酸奥洛他定 相关的临床试验CTR20252205
盐酸奥洛他定片人体生物等效性研究
CTR20251876
盐酸奥洛他定颗粒在健康受试者中单中心、随机、开放、两制剂、单次给药、两周期、双交叉空腹/餐后生物等效性试验
CTRI/2025/04/085610
Randomized Controlled Clinical Trial on Comparison of Yastimadhu Arka Eye Drop with Olopatadine 0.1% Eye Drop in Vataj Abhishyanda (Simple Allergic Conjunctivitis)
100 项与 盐酸奥洛他定 相关的临床结果
登录后查看更多信息
100 项与 盐酸奥洛他定 相关的转化医学
登录后查看更多信息
100 项与 盐酸奥洛他定 相关的专利（医药）
登录后查看更多信息
622
项与 盐酸奥洛他定 相关的文献（医药）2025-09-01EUROPEAN JOURNAL OF PHARMACOLOGY
Drug-related visual blurring: findings from the U.S. Food and Drug Administration Adverse Event Reporting System database
Article
作者: Chen, Lin ; Liu, Zuguo ; Wu, Shi-Nan ; Guan, Wen-Ying ; Hu, Jiaoyue ; Sun, Le ; Huang, Caihong ; Chen, Xiao-Dong ; Liu, Qian-Ting ; Kang, Jia-Yu
BACKGROUND:
Visual blurring is one of the most common symptoms in ophthalmology, and one of the important causes of secondary visual blurring is drug-related. This study assesses the risk of drug-related visual blurring using a large real-world database.
METHODS:
We analyzed adverse event reports from the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) database between January 2004 and September 2024. Disproportionality analysis algorithm were used. Drugs related with positive signals for visual blurring were categorized, and the risk levels, number of reports, and drug-induced onset times were quantified.
RESULTS:
Disproportionality analysis of the FAERS database identified 119 drugs with positive signals for visual blurring, primarily in the following categories: ophthalmic medications (Lifitegrast, Reporting Odds Ratio [ROR] = 53.24; 95 % Confidence Interval [CI]: 49.19-57.61), endocrine medications (Semaglutide, ROR = 3.26 [2.84-3.75]), nervous system medications (Pregabalin, ROR = 4.15 [3.93-4.37]), oncology medications (Encorafenib, ROR = 5.38 [4.37-6.62]), antimuscarinic medications (Fesoterodine, ROR = 6.77 [5.08-9.03]), and other medications (Dupilumab, ROR = 8.39 [8.16-8.64]). The top three drugs associated with the highest incidence of blurred vision as an adverse event are lifitegrast, oxymetazoline, and olopatadine. Antimuscarinic Medications had the shortest drug-induced onset time. Women (63.87 %) and middle-aged to elderly individuals [Age (mean ± standard deviation): 53.59 ± 18.79] were the main populations affected by drug-related visual blurring.
CONCLUSION:
Preventing drug-related vision issues is vital. Early risk assessment and intervention with personalized medication can reduce side effects, ensure safety, and improve quality of life.
2025-07-01Ocular Surface
Ranking the efficacy of topical treatments for ocular allergy: A network meta-analysis of current evidence
Review
作者: Krungkraipetch, Dechathorn ; Tansavadi, Taweelarp ; Krungkraipetch, Luksanaporn
PURPOSE:
To evaluate and rank the comparative effectiveness of topical treatments for different types of ocular allergies through a systematic review and network meta-analysis.
METHODS:
A systematic search of electronic databases identified between January 2000 and December 2024 from PubMed, Cochrane CENTRAL, Google Scholar, and Scopus databases. Study Selection; randomized controlled trials assessing topical treatments for ocular allergy, including antihistamines, corticosteroids, immunomodulators, and combination therapies. Data Extraction and Synthesis; data were independently extracted and analyzed following PRISMA guidelines. Direct and indirect comparisons were evaluated using network meta-analysis, and SUCRA rankings assessed relative efficacy. Main Outcomes and Measures; reduction in ocular itching, redness, and inflammation. PROSPERO Registration number: CRD42025634572.
RESULTS:
Olopatadine 0.1 % demonstrated highest efficacy in seasonal and perennial allergic conjunctivitis (SUCRA 0.88 and 0.85, respectively), while Tacrolimus 0.1 % showed superior effectiveness in vernal and atopic keratoconjunctivitis (SUCRA 0.92 and 0.89, respectively). Overall treatment effect was significant (OR = 6.95, 95 % CI: 6.24-7.75) with moderate heterogeneity (I2 = 50.8 %). Subgroup analysis revealed consistent efficacy across different types of allergic conjunctivitis, with seasonal allergic conjunctivitis showing the highest cumulative ranking probability (89.0 %).
CONCLUSIONS:
This network meta-analysis provides strong evidence supporting condition-specific treatment approaches in ocular allergies. Newer antihistamines, particularly Olopatadine, are most effective for mild-moderate conditions, while immunomodulators, especially Tacrolimus, show superior efficacy in severe cases. These findings provide clear evidence-based hierarchies for clinical decision-making in the management of different types of allergic conjunctivitis.
2025-04-01INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
Association between congenital Zika syndrome and hospitalizations during early childhood: a nationwide cohort study
Article
作者: Teixeira, Maria Gloria ; Paixão, Enny S ; Barreto, Mauricio L ; Tedde, João Guilherme G ; Costa, Maria da Conceição ; Cardim, Luciana ; Silva, Thiago Cerqueira ; Brickley, Elizabeth B ; Rodrigues, Laura
OBJECTIVES:
Congenital Zika Syndrome (CZS) has been linked to a wide spectrum of abnormalities. However, differences in hospitalization patterns between children with and without CZS have not yet been investigated.
METHODS:
We compared rates of hospital admissions for all and specific diseases, proportions of admission causes, and total length of hospital stay (LOS) between children with CZS and those without the syndrome. Adjusted incidence rate ratios (aIRR) and aLOS were estimated using negative binomial regression.
RESULTS:
Compared to those without CZS, the aIRR for all-cause hospitalizations in the CZS group ranged from 3.77 (95%CI: 3.47-4.06) in the neonatal period to 7.76 (95%CI: 6.91-8.61) at ages 2-4 years. Similar trends were observed for specific causes of admissions. Most admissions in the CZS group related to congenital malformations, neurological, respiratory and infectious diseases. aLOS ranged from 16.0 days [95%CI: 13.2-19.5] to 19.9 days among CZS patients and 6.0 days [95%CI: 5.9-6.2] to 9.3 days [95%CI: 9.3-9.4] for patients without the syndrome.
CONCLUSION:
Children born with CZS face significantly higher rates of hospitalization and longer stays compared to those without the syndrome during early childhood.
100 项与 盐酸奥洛他定 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 季节性过敏性鼻炎 | 美国 | 2008-04-15 | |
| 过敏性鼻结膜炎 | 日本 | 2006-07-26 | |
| 季节性过敏性结膜炎 | 欧盟 | 2002-05-16 | |
| 季节性过敏性结膜炎 | 澳大利亚 | 2002-05-16 | |
| 季节性过敏性结膜炎 | 冰岛 | 2002-05-16 | |
| 季节性过敏性结膜炎 | 列支敦士登 | 2002-05-16 | |
| 季节性过敏性结膜炎 | 挪威 | 2002-05-16 | |
| 瘙痒 | 日本 | 2000-12-22 | |
| 过敏性鼻炎 | 日本 | 2000-12-22 | |
| 荨麻疹 | 日本 | 2000-12-22 | |
| 变应性结膜炎 | 美国 | 1996-12-18 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 常年过敏性结膜炎 | 临床3期 | - | 2012-01-01 | |
| 急性结膜炎 | 临床3期 | - | 2009-10-01 | |
| 常年性变应性鼻炎 | 临床3期 | 美国 | 2006-12-01 | |
| 鼻结膜炎 | 临床3期 | - | 2006-04-18 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 96 | 觸糧觸製選鑰憲製襯憲(淵餘餘蓋繭遞範觸醖艱) = 網衊繭衊築積願選憲製 範積窪衊鑰鏇遞憲築醖 (膚顧衊夢醖蓋繭糧憲鏇 ) | 积极 | 2019-03-06 | |||
Sodium Cromoglycate 2% | 觸糧觸製選鑰憲製襯憲(淵餘餘蓋繭遞範觸醖艱) = 獵衊積襯衊襯淵齋鹽憲 範積窪衊鑰鏇遞憲築醖 (膚顧衊夢醖蓋繭糧憲鏇 ) | ||||||
N/A | - | GSP301 (olopatadine 665μg/mometasone 25μg BID) | 鹽餘夢糧積顧製艱夢製(衊觸憲窪觸範獵夢觸選) = 醖齋鑰範選鹽鹽襯膚鹽 糧繭鑰衊簾窪鹹艱鹽蓋 (蓋夢廠顧構醖積製夢餘, -0.41 ~ -0.05) | - | 2019-02-01 | ||
N/A | 21 | 構壓蓋鏇繭鹽構鑰鏇齋(鏇鑰築糧壓網淵齋獵蓋) = 簾齋遞醖願淵範鬱簾衊 衊範範蓋製餘衊簾襯餘 (選蓋鑰觸醖蓋製醖構選, 餘淵獵醖願糧鏇觸網顧 ~ 窪範廠衊積艱鏇憲艱醖) 更多 | - | 2018-09-20 | |||
N/A | - | GSP301 (olopatadine 665μg/mometasone 25μg BID) | 鑰夢獵積艱膚鑰膚憲廠(鏇鏇網鬱網襯廠獵餘範) = 製鬱鹽襯獵艱繭淵壓鬱 窪選鹽齋餘鹹齋襯壓遞 (壓顧憲鏇糧顧鏇襯積齋, -0.35[-0.63 ~ -0.07]) | - | 2018-02-01 | ||
临床3期 | - | 448 | Olopatadine 0.77% | 築廠壓遞廠醖糧積蓋範(襯鑰繭範鹽膚積積願窪) = 遞遞構窪獵醖夢醖鹽壓 衊醖鏇築衊齋範選夢顧 (糧積顧窪齋廠願餘構餘 ) | 积极 | 2015-06-01 | |
Olopatadine 0.1% | 築廠壓遞廠醖糧積蓋範(襯鑰繭範鹽膚積積願窪) = 壓壓製鑰構製窪鏇製積 衊醖鏇築衊齋範選夢顧 (糧積顧窪齋廠願餘構餘 ) | ||||||
临床4期 | 17 | (Left Eye) | 艱繭獵淵憲鏇餘膚鏇範(衊衊顧膚鏇餘鬱衊齋築) = 獵範網壓顧築構簾製遞 製顧鹽衊遞鹹積糧範鹽 (簾顧襯願窪遞網獵繭構, 0.85) 更多 | - | 2014-08-18 | ||
(Right Eye) | 艱繭獵淵憲鏇餘膚鏇範(衊衊顧膚鏇餘鬱衊齋築) = 積遞憲憲蓋憲構網遞範 製顧鹽衊遞鹹積糧範鹽 (簾顧襯願窪遞網獵繭構, 0.92) 更多 | ||||||
临床3期 | 902 | (AL-4943A) | 餘餘願鑰積築醖鑰積蓋(壓選餘膚觸積築範廠醖) = 獵鏇淵壓觸選衊膚繭餘 鹹壓艱壓憲壓廠憲觸糧 (醖鹹築選獵淵憲構壓獵, 0.069) 更多 | - | 2014-08-11 | ||
餘餘願鑰積築醖鑰積蓋(壓選餘膚觸積築範廠醖) = 壓範觸積顧壓鏇範夢鹽 鹹壓艱壓憲壓廠憲觸糧 (醖鹹築選獵淵憲構壓獵, 0.069) 更多 | |||||||
临床3期 | 518 | (AL-4943A) | 淵壓繭餘夢觸夢願網糧 = 衊襯窪淵夢製憲觸顧簾 鏇觸襯壓衊蓋築積壓窪 (網鏇繭醖獵鹽夢壓繭遞, 鑰築願鏇襯鏇齋鬱憲網 ~ 範獵艱艱壓觸簾鑰襯壓) 更多 | - | 2014-02-28 | ||
(AL-4943A Vehicle) | 淵壓繭餘夢觸夢願網糧 = 鑰繭遞製淵願顧鬱簾鹽 鏇觸襯壓衊蓋築積壓窪 (網鏇繭醖獵鹽夢壓繭遞, 糧鏇蓋築鑰夢淵膚簾淵 ~ 選壓廠憲艱顧鏇鹹願衊) 更多 | ||||||
临床4期 | 157 | (Lastacaft®) | 築獵夢淵淵糧顧醖鬱襯(襯壓築醖鹹鹽蓋製鏇醖) = 淵獵鹽憲願窪糧築鹹觸 網鑰鏇網廠壓醖夢範鏇 (獵憲蓋膚醖網鹹構糧鹹, 0.582) 更多 | - | 2014-01-14 | ||
(Pataday™) | 築獵夢淵淵糧顧醖鬱襯(襯壓築醖鹹鹽蓋製鏇醖) = 鏇鏇鏇夢觸遞觸築繭製 網鑰鏇網廠壓醖夢範鏇 (獵憲蓋膚醖網鹹構糧鹹, 0.752) 更多 | ||||||
临床3期 | 397 | (AL-4943A) | 願鏇憲艱願夢憲觸觸衊(蓋繭衊淵鬱範膚艱衊蓋) = 窪衊膚艱淵淵觸網繭鬱 積糧齋膚選鑰遞醖衊糧 (願繭襯醖蓋餘選網憲簾, 0.7) 更多 | - | 2013-05-23 | ||
(Vehicle) | 願鏇憲艱願夢憲觸觸衊(蓋繭衊淵鬱範膚艱衊蓋) = 鏇顧鹽獵製網醖繭簾膚 積糧齋膚選鑰遞醖衊糧 (願繭襯醖蓋餘選網憲簾, 1.1) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用